Looking into the "Garden of the Hesperides": new drugs for hepatocellular carcinoma
Advanced hepatocellular carcinoma remains an entity that is hard to approach therapeutically and has shown disappointing results in terms of survival. For many years, the only accepted option for this setting was the use of a multikinase inhibitor, sorafenib. Nevertheless, through the years, a deeper knowledge has arisen about how pathogenic pathways correlate with hepatocellular carcinoma. In this review, we provide an update of the most recent data regarding new agents under investigation and new possible targets for future treatments..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2015 |
---|---|
Erschienen: |
2015 |
Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
---|---|
Enthalten in: |
Minerva chirurgica - 70(2015), 2, Seite 119 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Castañón Alvarez, E [VerfasserIn] |
---|
Links: |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
OLC1956376755 |
---|
LEADER | 01000caa a2200265 4500 | ||
---|---|---|---|
001 | OLC1956376755 | ||
003 | DE-627 | ||
005 | 20230514003530.0 | ||
007 | tu | ||
008 | 160206s2015 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a PQ20160617 |
035 | |a (DE-627)OLC1956376755 | ||
035 | |a (DE-599)GBVOLC1956376755 | ||
035 | |a (PRQ)p837-65d026ee6c0ce432c21d54055b30c196a6051376e42429ee90c9dfc7e96122df0 | ||
035 | |a (KEY)0116342620150000070000200119lookingintothegardenofthehesperidesnewdrugsforhepa | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q DNB |
100 | 1 | |a Castañón Alvarez, E |e verfasserin |4 aut | |
245 | 1 | 0 | |a Looking into the "Garden of the Hesperides": new drugs for hepatocellular carcinoma |
264 | 1 | |c 2015 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
520 | |a Advanced hepatocellular carcinoma remains an entity that is hard to approach therapeutically and has shown disappointing results in terms of survival. For many years, the only accepted option for this setting was the use of a multikinase inhibitor, sorafenib. Nevertheless, through the years, a deeper knowledge has arisen about how pathogenic pathways correlate with hepatocellular carcinoma. In this review, we provide an update of the most recent data regarding new agents under investigation and new possible targets for future treatments. | ||
650 | 4 | |a TOR Serine-Threonine Kinases - therapeutic use | |
650 | 4 | |a Carcinoma, Hepatocellular - metabolism | |
650 | 4 | |a Proto-Oncogene Proteins c-met - antagonists & inhibitors | |
650 | 4 | |a Liver Neoplasms - drug therapy | |
650 | 4 | |a Liver Neoplasms - metabolism | |
650 | 4 | |a Angiogenesis Inhibitors - therapeutic use | |
650 | 4 | |a Wnt Signaling Pathway - drug effects | |
650 | 4 | |a Liver Neoplasms - therapy | |
650 | 4 | |a Multiprotein Complexes - pharmacology | |
650 | 4 | |a Multiprotein Complexes - therapeutic use | |
650 | 4 | |a Immunotherapy - methods | |
650 | 4 | |a TOR Serine-Threonine Kinases - pharmacology | |
650 | 4 | |a Carcinoma, Hepatocellular - therapy | |
650 | 4 | |a Carcinoma, Hepatocellular - drug therapy | |
650 | 4 | |a Antineoplastic Agents - therapeutic use | |
700 | 1 | |a Giallombardo, M |4 oth | |
700 | 1 | |a Gil-Bazo, I |4 oth | |
700 | 1 | |a Papadimitriou, K |4 oth | |
700 | 1 | |a Pauwels, P |4 oth | |
700 | 1 | |a Peeters, M |4 oth | |
700 | 1 | |a Rolfo, C |4 oth | |
773 | 0 | 8 | |i Enthalten in |t Minerva chirurgica |d Torino : Ed. Minerva Medica, 1946 |g 70(2015), 2, Seite 119 |w (DE-627)166185175 |w (DE-600)123603-9 |w (DE-576)014497484 |x 0026-4733 |7 nnns |
773 | 1 | 8 | |g volume:70 |g year:2015 |g number:2 |g pages:119 |
856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25614940 |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4219 | ||
951 | |a AR | ||
952 | |d 70 |j 2015 |e 2 |h 119 |